Cell and Gene Therapy Market to Reach USD 128.8 Million by 2035

According to analysts at Vantage Market Research, the Global Cell and Gene Therapy Market size is worth USD 20.5 Billion in 2024 and is projected to reach USD 128.8 Billion by 2035, growing at a CAGR (Compound Annual Growth Rate) of 18.2% from 2024 to 2035. Key trends of market include expanding gene-editing technologies, increased regulatory approvals, growing partnerships between biotech firms, advancements in viral vector development, and rising focus on rare genetic disorders.

Market Overview

The development of more efficient and precise gene-transfer technologies, such as CRISPR and viral vectors, presents significant opportunities for the market. These advancements can improve the effectiveness and safety of gene therapies, making them more accessible and viable for a broader range of diseases. Additionally, there is an increasing focus on rare diseases, which often lack effective treatments. Gene therapies have the potential to address these unmet needs, offering significant growth potential as companies develop targeted therapies for these conditions.

The increasing prevalence of genetic disorders, cancers, and chronic diseases has led to a growing demand for innovative treatments. Cell and gene therapies offer targeted solutions that can potentially cure or significantly improve the outcomes of diseases that were previously difficult to treat. As patients and healthcare providers seek more effective and personalized treatment options, the demand for these advanced therapies continues to rise, driving market growth.

Pfizer Acquires Biohaven Pharmaceuticals to Expand Migraine Treatment Options

• In October 3, 2022, Pfizer announced the successful acquisition of Biohaven Pharmaceuticals, a company specializing in migraine drugs. Biohaven's NURTEC ODT (rimegepant), approved for acute therapy and episodic migraine prevention in adults, will expand Pfizer's offerings, providing more treatment options for migraine patients globally

Key Takeaways from the Report

• In 2024, North America dominated the market  with 47.8% of market share. The market is driven by the presence of advanced healthcare infrastructure, and significant investments in R&D
• Based on the Therapy Type, the Cell Therapy category accounted for significant market share in market for 85.6% in 2024. The widespread application of cell-based treatments, such as stem cell therapies and CAR-T therapies, which are being increasingly used to treat various diseases, including cancers and genetic disorders
• In 2024, by Therapeutic class, Infectious Disease dominated the market share of 13.4%. The segment is driven by advancements in gene-editing technologies, increasing prevalence of infectious diseases, and rising demand for innovative treatment options
• By Delivery Method, in vivo dominated the largest market share in 2024. 
• In 2024, Based on End-Users, Cancer Care Centers dominated the largest market share of 78.5%. The segment is driven by rising prevalence of cancer and the increasing adoption of advanced cell and gene therapies as standard treatment options

Top Companies

• Alnylam Pharmaceuticals Inc.
• Amgen Inc.
• Biogen Inc.
• CORESTEM Inc.
• Dendreon Pharmaceuticals LLC.
• Helixmith Co. Ltd.
• JCR Pharmaceuticals Co. Ltd.
• Kolon TissueGene Inc.
• Novartis AG
• Pfizer Inc.

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional market landscapes, and evaluate the impact of major events like the COVID-19 pandemic. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, providing actionable intelligence to empower your business strategies.

Latest News

Alexion Acquires LogicBio's Technology to Enhance Gene Therapy for Rare Diseases

• In October 3, 2022, Alexion's Genomic Medicines announced the acquisition of LogicBio's technology. This acquisition aims to integrate LogicBio's expertise in preclinical development and rare disease research and development. LogicBio has developed various systems for gene delivery to address genetic disorders and will also help enhance the creation of viral vectors through their platform